Possible MCC market with colon/ovarian?Also of note from the February 13 news release:
"MCC is a sterile mycobacterial cell wall composition that has a dual mode of action: immune stimulation and direct anticancer activity. It is formulated as Urocidin(TM) for the treatment of bladder cancer, where it is administered by the intravesical route directly into the bladder, coming into contact with immune system cells and bladder cancer cells. MCC is also undergoing preclinical evaluation as a treatment for peritoneal carcinomatosis associated with colon and ovarian cancer."
So, it looks like in addition to Bladder cancer which is the seventh most common cancer malignancy, MCC is also being evaluated for its potential in treating colon and ovarian cancer. I don't know where those two cancers rate as to commmon occurence, but they must be quite high on the list. The study for colon/ovarian treatment doesn't appear to be too advanced yet, but would have huge implications if MCC proves successful in that direction.